Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Streptococcus pyogenes Infections - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Streptococcus pyogenes Infections - Pipeline Review, H1 2016', provides an overview of the Streptococcus pyogenes Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections - The report reviews pipeline therapeutics for Streptococcus pyogenes Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Streptococcus pyogenes Infections therapeutics and enlists all their major and minor projects - The report assesses Streptococcus pyogenes Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Streptococcus pyogenes Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Streptococcus pyogenes Infections Overview 6 Therapeutics Development 7 Pipeline Products for Streptococcus pyogenes Infections - Overview 7 Pipeline Products for Streptococcus pyogenes Infections - Comparative Analysis 8 Streptococcus pyogenes Infections - Therapeutics under Development by Companies 9 Streptococcus pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 10 Streptococcus pyogenes Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Streptococcus pyogenes Infections - Products under Development by Companies 13 Streptococcus pyogenes Infections - Products under Investigation by Universities/Institutes 14 Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development 15 Absynth Biologics Limited 15 AstraZeneca Plc 16 Emergent BioSolutions Inc. 17 Helix BioMedix, Inc. 18 Sumitomo Dainippon Pharma Co., Ltd. 19 Wellstat Vaccines, LLC 20 Streptococcus pyogenes Infections - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 ATx-201 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AZ-6142 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 EV-035 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 group A Streptococcus vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 HB-1345 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SM-295291 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SM-369926 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Streptococcus pyogenes vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Streptococcus pyogenes vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 streptococcus pyogenes vaccine (30-valent) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Streptococcus pyogenes Infections - Recent Pipeline Updates 44 Streptococcus pyogenes Infections - Dormant Projects 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Streptococcus pyogenes Infections, H1 2016 7 Number of Products under Development for Streptococcus pyogenes Infections - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Limited, H1 2016 15 Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H1 2016 16 Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 17 Streptococcus pyogenes Infections - Pipeline by Helix BioMedix, Inc., H1 2016 18 Streptococcus pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 19 Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Streptococcus pyogenes Infections Therapeutics - Recent Pipeline Updates, H1 2016 44 Streptococcus pyogenes Infections - Dormant Projects, H1 2016 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.